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compare guideline-adherent and routine clinical practice. Value of information analy-
sis will be employed to identify areas for future research. We are applying this trans-
lational approach to various current and developing examples of PM in cancer: 1) 
trastuzumab for human-epidermal growth factor receptor-2 positive BC; 2) gene-
expression proﬁling to identify patients who will beneﬁt most from adjuvant treatment 
in BC; 3) cytochrome P450 2D6 testing to select patients for adjuvant tamoxifen 
therapy in BC; and 4) testing for Lynch Syndrome in CRC patients and their family 
members to inform treatment and preventative interventions. This research will 
develop evidence-based information for patients, providers, industry, researchers and 
policymakers to objectively assess how PM can be beneﬁcial and efﬁcient in improving 
cancer outcomes.
PODIUM SESSION III: RESEARCH ON THE USE OF UTILITY 
MEASUREMENT
UT1
ASSOCIATION BETWEEN UTILITY AND TREATMENT AMONG 
PROSTATE CANCER PATIENTS
Jayadevappa R, Chhatre S, Malkowicz B
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To analyze the association between utility, treatment and generic and 
prostate-speciﬁc health related quality of life (HRQoL) among prostate cancer 
patients. METHODS: In this longitudinal cohort study we recruited 201 (≥45 yrs) 
newly diagnosed prostate cancer patients from urology clinics of an urban academic 
hospital. Participants completed Quality of Wellbeing (QWB-SA), generic (SF-36) and 
prostate-speciﬁc (UCLA-PCI) HRQoL surveys prior to treatment and up to 24 months 
post-treatment. Clinical and demographic data were obtained via medical chart review 
and utility scores were computed using QWB-SA. To analyze the relationship between 
treatment and utility we used linear mixed effects models, after adjusting for covari-
ates. Similar models were used to examine association between generic and prostate-
speciﬁc HRQoL and utility. RESULTS: Mean baseline utility was comparable between 
radical prostatectomy (RP) and external beam radiation therapy (EBRT) groups (0.73 
vs. 0.69, p = 0.1750). Mixed effects models indicated that RP was associated with 
higher utility at 24 month (OR = 1.12, p = 0.027), after controlling for covariates. 
RP was associated with improved functioning for role physical, role emotional, vital-
ity, mental health and bodily pain and impaired urinary function. Higher scores on 
generic health subscales were indicative of higher utility. Also, for prostate-speciﬁc 
HRQoL, higher scores on bowl function, sexual function, urinary bother and bowel 
bother were associated higher utility. CONCLUSIONS: Treatment appears to have 
signiﬁcant association with post-treatment utility. Thus, utility assessment provides an 
important quantitative tool to support patient and physician clinical treatment deci-
sion making process of prostate cancer care.
UT2
COMPARISON OF HEALTH STATE UTILITY ESTIMATES IN  
COST-EFFECTIVENESS ANALYSIS
Slejko JF1, Ghushchyan VH1, Sullivan PW2
1University of Colorado Denver, Aurora, CO, USA, 2Regis University School of Pharmacy, 
Denver, CO, USA
OBJECTIVES: This study examined the effect of different utility instruments and 
tariffs on chronic condition utility scores and incremental cost-effectiveness ratios 
(ICERs). METHODS: Postponement of diabetes was modeled in a high-risk popula-
tion receiving a hypothetical intervention, as compared to a similar control group. 
Utility estimates for the general population, diabetes, hypertension, stroke, myocardial 
infarction (MI) and congestive heart failure (CHF) were taken from catalogues devel-
oped by Sullivan et al. for United States and United Kingdom EuroQOL-5D tariffs 
(EQ-5DUS and EQ-5DUK) and SF-6D, using the Medical Expenditure Panel Survey. 
Quality-adjusted life-years (QALYs) were modeled for 20 years using a 3% discount 
rate. The discounted cost of the intervention was assumed to be $150,000. RESULTS: 
The initial health state utility was lowest using the SF-6D(.709), and highest using 
EQ-5DUS(.800). The highest estimates for diabetes(.708), hypertension(.761) and 
MI(.575) were found using EQ-5DUS, but the highest stroke(.534) and CHF(.503) 
estimates were found with the SF-6D. The lowest estimates for stroke(.189), MI(.516) 
and CHF(.189) were from the EQ-5DUK, but the lowest estimates for hyperten-
sion(.583) and diabetes(.618) were from the SF-6D. The EQ-5DUK resulted in the 
largest marginal utility decrement for all conditions. The smallest decrement for 
hypertension(−.002) and diabetes(−.022) resulted from the SF-6D, but from the 
EQ-5DUS for stroke(−.069) and CHF(−.055). When these estimates were applied to 
the model, the resulting QALYs gained from the intervention were greatest from the 
EQ-5DUS(11.32) and least from the EQ-5DUK(9.77). Incremental QALYs gained 
were greatest for EQ-5DUK(3.278) and least for the SF-6D(2.880). The ICER varied 
from $46,000–$52,000 depending on the instrument/tariff. CONCLUSIONS: Differ-
ent utility instruments/tariffs resulted in unsystematic differences in chronic condition 
utilities, but the marginal decrement in each of these conditions was systematically 
lower for the EQ-5DUK and may be a trend across all conditions. Incremental QALYs 
gained differed by instrument/tariff and the ICER varied from $46,000–$52,000.
UT3
RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT 
AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL 
TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA 
(ALL) IN CHILDHOOD
Horsman JR1, Rae CS2, Furlong W1, Silverman LB3, Sallan SE3, Athale U2, Barr RD2
1Health Utilities Inc., Dundas, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3Harvard Medical School, Boston, MA, USA
OBJECTIVES: To assess differences in the reliability of HUI Mark 3 (HUI3) health-
related quality of life (HRQL) utility scores for patients between self and parent 
assessments across two Dana-Farber Cancer Institute (DFCI) clinical trials for treat-
ment of ALL during childhood. METHODS: Patients were enrolled in either the DFCI 
95-001 or 00-001trial, and were ≥12 years of age at the time of HUI survey. Patients 
and parents, blind to each other, completed HUI questionnaires at each of 5 trial 
phases: induction; CNS prophylaxis; intensiﬁcation; continuation; and post-treatment. 
Reliability was assessed in terms of inter-rater agreement of individual scores and 
differences in mean scores. Agreement was quantiﬁed using the single-measure 
two-way mixed model intra-class correlation coefﬁcient (ICC). An ICC of 0.41–0.60 
represents moderate reliability, 0.61–0.80 good reliability, and 0.81–1.00 very good 
reliability. Mean differences of >0.03 are clinically important. Statistical signiﬁcance 
was set at p < 0.05. RESULTS: The number of patient and parent paired assessments 
varied by assessment phase for both the 95-001 (minimum = 29, maximum = 50) and 
the 00-001 (minimum = 28, maximum = 54) trials. ICCs in the two trials ranged from 
0.49 (p < 0.05) to 0.88 (p < 0.05). There was substantial overlap of ICC 95% conﬁ-
dence bounds across the two trials at each of the ﬁve assessment phases. There was 
no signiﬁcant difference (p > 0.06) between patient-parent pairs of scores at any 
assessment phase in either trial. The difference between trials in mean patient-parent 
scores was ≤0.03 and insigniﬁcant (p > 0.08) for each of the 5 assessment phases. 
CONCLUSIONS: Agreement between patient and parent scores was moderate or 
better for all assessment phases in both trials. There were no important differences in 
mean patient and parent scores for any of the assessment phases of the two trials. 
Inter-rater reliability of scores was similar across the two trials. Parental assessments 
provide acceptable and consistent estimates of HRQL for children.
UT4
EVALUATING WILLINGNESS TO PAY THRESHOLDS FOR A DEMENTIA 
CAREGIVING INTERVENTION
Jutkowitz E, Gitlin L, Pizzi LT
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVES:—Assess the methodological challenges of evaluating appropriate will-
ingness to pay thresholds (WTP) in cost-effectiveness studies which do not use a 
societal perspective or a QALY outcome measure. METHODS:—Tailored Activity 
Program (TAP), an intervention designed to reduce caregiver burden for dementia 
patients, served as a case study. Caregiver interventions such as TAP employ an 
individual perspective and non-QALY outcome measures such that standard societal 
WTP thresholds are not applicable. Two outcome measures related to caregiver 
burden were used 1) reduction in hours “on duty,” and 2) reduction in hours “doing 
things.” To estimate appropriate WTP values for each TAP outcome measure, we 
identiﬁed three studies which met these inclusion criteria: 1) published studies in the 
past 5 years using contingent valuation methodology to identify WTP, 2) assessed 
WTP for a dementia-related intervention that required an out-of-pocket expenditure, 
and 3) asked caregivers what they would be willing to pay for an outcome of reducing 
caregiver burden. We also assessed WTP based on the potential ﬁnancial savings 
caregivers could achieve from purchasing TAP. To assess proportion of time TAP was 
cost-effective, we built a Monte Carlo simulation to test the four WTP values identi-
ﬁed. RESULTS:—For the outcome measure “on duty” WTP varied between $1.06/
hr–$4.58/hr. WTP for the outcome measure “doing things” varied between $2.21/
hr–$9.57/hr. Applying WTP values to TAP indicates TAP cost-effectiveness varies 
between 50%-80% for both outcome measures. CONCLUSIONS:—If WTP data can 
not be collected prospectively or societal values can not be applied, evaluating WTP 
using comparable studies appears to be an acceptable method for informing decisions 
makers of potential cost-effectiveness. Application of WTP to TAP shows potential 
cost-effectiveness that can be expected under different WTP scenarios.
POSTER SESSION I
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Clinical  
Outcomes Methods
PMC1
EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS 
FOR FDA REGULATORY APPROVALS
Nixon A, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Clinician reported outcomes (CROs) are the most commonly observed 
endpoint in FDA approved product labels (Wilke et al, 2004) but few have been 
adequately scrutinized in terms of their suitability as endpoints. This study evaluates 
four widely used CROs in order to assess their suitability as endpoints for regulatory 
approvals. METHODS: Published evidence on the Karnofsky Performance Status 
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Scale (KPS), Spitzer QOL-Index, Expanded Disability Status Scale (EDSS), and the 
Hamilton Rating Scale for Depression (HAM-D) were evaluated in terms of: concep-
tual framework; patient, literature and clinician contribution to development; process 
for deriving items; content validity; item reduction; linguistic and cultural adaptation; 
scoring; and reliability, validity, and ability to detect change. RESULTS: The FDA 
discourages the use of CROs for symptoms that can only be known to the patient, 
whereas clinical signs are usually observed and interpreted by the clinician. Despite 
the widespread use of the KPS as a classiﬁcation of functional status in patients with 
cancer, there is little data supporting the development, content validity, and statistical 
measurement properties of the scale. Among other critiques, the EDSS has question-
able inter-rater reliability. Although the Spitzer QOL-index was developed with 
patient input and has documented measurement properties, the use of proxy for QOL/
HRQL evaluations is widely discouraged. The HAM-D is considered the ‘gold stan-
dard’ of depression rating scales with good psychometric properties, but with ques-
tionable content validity. CONCLUSIONS: The suitability of the selected CROs as 
endpoints for regulatory approvals varied widely. CROs are essential and complimen-
tary primary and secondary endpoints for drug evaluations for the purpose of FDA 
regulatory submissions, it is likely that sponsors will face increasing FDA scrutiny of 
CRO endpoints for the purpose of label claims.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Cost Methods
PMC2
REVIEW OF PHARMACOECONOMIC RECOMMENDATIONS FOR THE 
DEFINITION OF A SOCIETAL PERSPECTIVE
Fisher M, Alnwick K
Heron Evidence Development Limited, Luton, UK
OBJECTIVES: To compare the ways pharmacoeconomic (PE) guidelines in European 
and North American countries deﬁne the societal perspective for economic evalua-
tions. METHODS: Full-text country-speciﬁc PE guidelines were obtained via the 
ISPOR website and where possible cross-referenced with Health Technology Assess-
ment (HTA) agency recommendations. The following countries were selected for 
comparison: Belgium, Canada, Finland, France, Italy, Norway, the The Netherlands, 
Portugal and Sweden. The cost categories considered for the societal perspective were 
assessed and compared between country guidelines. RESULTS: PE guidelines from 
eight of the selected countries identiﬁed speciﬁc cost categories for the societal perspec-
tive. Guidelines agreed that the direct costs associated with this perspective included 
costs to the health service, costs to other publicly funded services and costs to patients/
family. Costs of time lost by family/unpaid carers was considered by 6/8 guidelines, 
which differed in assigning the cost as direct or indirect. There were differences in the 
indirect costs considered; costs of time lost by patients was only considered by 2/8 
guidelines. Intangible costs were considered by 4/8 guidelines, although it was gener-
ally accepted that these should be accounted for in the outcome measurement rather 
than through costs. Productivity loss was considered as an indirect cost by nine 
guidelines; however the preferred method of derivation differed between guidelines: 
2/9 guidelines preferred the Friction Cost Method (FCM) and 3/9 guidelines preferred 
the Human Capital Method (HCM). Moreover, there were differing views regarding 
the types of productivity loss to include: Portugal recommended consideration of 
employee-related loss only, whereas Canada also included loss to the employer associ-
ated with hiring new staff. CONCLUSIONS: There are subtle differences between the 
ways the societal perspective is deﬁned by PE guidelines in Europe and North America. 
This should be considered when devising evidence generation activities to support 
economic modelling, and may ultimately impact the outcome of HTA decisions.
PMC3
REVIEW OF COST EFFECTIVENESS ANALYSES THAT INCORPORATE 
NUMBER NEEDED TO TREAT/HARM VALUES
Raisch DW, Nawarskas JJ
University of New Mexico College of Pharmacy, Albuquerque, NM, USA
INTRODUCTION: Number needed to treat/harm (NNT/NNH) values are universally 
understood and applied by clinical decision makers. Therefore providing these values 
alongside cost effectiveness analysis (CEA) results may increase the relevance and 
clarify clinical implications of CEAs to decision makers. OBJECTIVES: To review the 
literature of CEA studies that incorporate NNT/NNH values. METHODS: We 
searched Pub Med using the Mesh term “cost-beneﬁt analysis” and “number needed 
to treat “, “number needed to harm”, “NNT”, or “NNH”. We included CEA studies 
and studies describing relationships between NNT/NNH and quality adjusted life 
years (QALYs) published in English. RESULTS: There were 102 publications identi-
ﬁed. Of these 47 provided both CEA and NNT/NNH results. There were 43 (91.5%) 
studies published in clinician-focused practice journals, 2 (4.3%) in policy journals, 
and 2 (4.3%) in economic journals. The CEA incorporated NNT/NNH directly as 
part of the CEA ratio in 23 (48.9%) studies and CEA was separately stated from 
NNT/NNH in 14 (29.8%) studies. The CEA was expressed as cost per QALY dis-
tinctly from NNT/NNH in 10 (21.3%). The focuses of the articles were disease 
treatments in 28 (59.5%) studies, disease prevention in 15 (31.9%), and patient educa-
tion or disease management in 2 (4.3%) each. Also, there were 4 studies regarding 
relationships between NNT/NNH and QALYs. CONCLUSIONS: We found that the 
majority of articles incorporating NNT/NNH into CEA were published in clinical 
practice journals and most involved comparisons of speciﬁc disease treatments. Incor-
porating NNT/NNH into CEA results may improve relevance to clinical decision-
making, but further research is needed regarding how they are best integrated. One 
alternative may include weighting NNT/NNH values for different outcomes in terms 
of QALYs.
PMC4
THE DERIVATION OF TRICARE SPECIFIC CONSUMER PRICE INDICES 
FOR PRESCRIPTION DRUGS
Summers CR
TRICARE Management Activity, Falls Church, VA, USA
OBJECTIVES: One of the chronic issues in pharmaceutical utilization management is 
the dearth of accurate price benchmarks available to establish pharmacy-pricing 
performance. This paucity of appropriate benchmarks is further complicated for 
organizations, such as TRICARE, who have reason to believe that their demographics 
and hence disease proﬁles yield atypical prescription drug market baskets. Thus, to 
obtain an accurate assessment of organizational performance, organization-speciﬁc 
indices need to be developed. METHODS: A unique approach to developing organiza-
tion speciﬁc benchmarks is underway in a joint venture between the TRICARE 
Pharmaceutical Operations Directorate (POD) and the US Bureau of Labor Statistics 
(BLS). The primary method is to match retail pricing information provided by BLS 
and portfolio information provided by TRICARE to construct organization speciﬁc 
benchmarks that can be tracked over time. Variables from the Consumer Price Index 
for Prescription Drugs (CPI-Rx) are transferred to the POD as speciﬁed in an inter-
governmental memorandum of understanding. To form an overall TRICARE-Rx 
index for a speciﬁc month, all TRICARE prescription data are aggregated by speciﬁc 
drug and the number of prescriptions is computed for each drug for speciﬁc month 
using a ﬁle extracted from the Pharmacy Data Transaction Service (PDTS). CPI-Rx 
prices are then aggregated by same list of unique drugs used in the TRICARE sample 
then averaged in a separate ﬁle. The ﬁles are then merged using NDC codes as the 
key. The index is computed using the average CPI-Rx price for each speciﬁc drug 
multiplied by the TRICARE N for the corresponding drugs then averaged. CONCLU-
SIONS: TRICARE spends roughly $7.5 Billion annually for prescription drugs. With 
the development of these indices, we can better gauge our cost containment priorities 
and efforts. This will help us determine if increases in costs are due to general drug 
price inﬂation speciﬁc to our unique market basket of drugs.
PMC5
VALIDATING A WEB-BASED INCREMENTAL COST-EFFECTIVENESS 
SOFTWARE PROGRAM THAT USES A MARKOV TRANSITION 
PROBABILITY MATRIX ANALYSIS MODEL
McGhan W, Zaveri V, Willey VJ, Gohil N
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: Commercial software can be expensive when conducting pharmaco-
economic analyses. We developed a free web-based software program, which incor-
porates Markov transition probabilities to compare the cost-effectiveness of any two 
treatments. The web-based software program was based on the model described in a 
decision modeling for health economic evaluation textbook, edited by A. Briggs. This 
Markov web-based software program calculates the incremental cost-effectiveness 
based on Markov matrices using multi-state transition probabilities, along with cor-
responding Markov state costs and utilities and graphically displays the results, using 
JavaScript algorithms and is available free at www.healthstrategy.com. The variable 
inputs for two treatment options include state transition probabilities, number of 
cycles, cost per state, and utility per state. The software creates a plot of incremental 
costs versus incremental utilities in cost-effectiveness quadrants; and with death as an 
absorbing state, also graphs life expectancy curves for two treatment comparisons. 
The objective of this study was to validate this free web-based software. METHODS: 
The Excel spreadsheet structure and data downloaded from the web for the speciﬁc 
example described in the modeling textbook were used as the reference case. 
RESULTS: For the example used, considering four transition states for each therapy 
option, and 20 cycles with no discounting, the MS Excel spreadsheet model versus 
the web-based JavaScript software compared as follows: average incremental US dollar 
costs: ($67701 vs. $67853), average incremental utility: (5.89 vs. 5.90) and average 
incremental cost-effectiveness ratio:($11500 vs. $11494). CONCLUSIONS: This free 
web-based Markov matrix JavaScript program gives similar results as the MS Excel 
spreadsheet model. With this free software, the user can input their own therapy 
parameters, and generate incremental costs, incremental utilities, life expectancy 
curves, and incremental cost effectiveness ratios. This free web-based software has 
potential beneﬁt as an educational tool for students and health professionals interested 
in exploring these analytical approaches.
PMC6
USE OF CLINICAL SIMULATION CENTERS TO CONDUCT PATIENT-
CENTERED TIME-AND-MOTION SIMULATIONS AS A BASIS FOR 
ECONOMIC ANALYSIS
Nickman N, Haak S, Kim J
University of Utah, Salt Lake City, UT, USA
BACKGROUND: Patient-centered professional practice and technology assessment 
research performed in health professional schools’ clinical simulation centers is a novel 
concept. Opportunities can be created for multidisciplinary collaboration relative to 
evaluation of medication regimen and device complexity. Micro-level costs can then 
be assigned and economic analysis conducted in a more precise fashion than in tradi-
tional clinical trials or database outcomes analysis. METHODS: One university’s 
pharmacy and nursing schools’ clinical simulation centers were used in two separate 
projects to conduct time-and-motion and activity-based costing analyses speciﬁc to 
